2.1
Iptacopan (Fabhalta, Novartis) is indicated as 'monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia'.
2 Information about iptacopan
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for iptacopan.
Price
2.3
The list price for iptacopan is £26,500 per 56‑pack of 200 mg capsules (excluding VAT; company submission).
2.4
The company has a commercial arrangement. This makes iptacopan available to the NHS with a discount. The size of the discount is commercial in confidence.